Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A lung on a chip developed by Harvard University Wyss Institute on a DARPA grant. Photo: DARPA

The Defense Advanced Research Projects Agency is known for creative, high-tech research projects that often sound like science fiction. Now, a philanthropic heavyweight and a former DARPA program director together are pushing for the federal government's health department to have its own version.

The big questions: How would it fit in the health department that also includes the National Institutes of Health? And how will pharmaceutical and other companies be incentivized to take products to market? The answers — and some clever navigating of the potential tensions — could help determine whether an Advanced Research Projects Agency for Health, or HARPA, ever gets off the ground.

The players: Bob Wright, the former CEO of NBC and founder of Autism Speaks, is the main force behind the proposal. He's tapped Geoffrey Ling, a neurologist at Johns Hopkins and the former director of DARPA's Biological Technologies Office, to develop the proposed agency and, Wright hopes, lead it.

DARPA gave us the internet, and both say it is worth seeing what the same model could do for much-needed advances in detecting and treating cancers and other diseases.

How it could work: Ling maintains it would complement the discovery work done at NIH: "I'm not saying that HARPA is a panacea and is going to fill all the need areas but it is an approach I can see filling part of these need areas. In my mind, it is just a different way of doing business. It's an entirely different philosophy."

The details: They advocate setting up a semi-autonomous body directly under the Department of Health and Human Services — but independent from NIH.

  • HARPA, like DARPA, would be "performance-based, milestone-driven, timeline-driven with the efforts determined by the government," Ling says.
  • It would center on contracts between the agency and researchers spanning academia, corporate and government agencies.

Harvard's David Walt, who is not involved in the proposal and was a chair of a now-defunct advisory council of DARPA, says if an ARPA health program is set up correctly and follows the DARPA model closely, it could benefit the health arena. But he points out that health care is a highly regulated environment. "I'd be excited about the prospect of bringing a DARPA-like approach to critical problems in health care but it isn't the same as implementing a new device in the military."

What NIH is doing: Taking science from the "bench to bedside" is within the NIH purview — director Francis Collins set up an institute to do just that. And, right now, the NIH can bypass the grant process and distribute funds through a DARPA-like arm called the Common Fund. Their 2017 budget is about $675 million.

About two-thirds of the work within that fund is toward goals set by the NIH with investigators coming up with ways to attempt to reach them, says Betsy Wilder, who directs the Office of Strategic Coordination at the NIH. DARPA also funds biotechnology projects and collaborates with NIH.

The ask: Wright and Ling want two separate chains of command under HHS and two separate budgets within the department.

  • Ling estimates the agency would require a budget of $2 to 3 billion — the equivalent of about 10% of the NIH's $34 billion for this year.
  • "We'll be the little sister to the NIH. No problem. But because of the different philosophy and because of the different approach, it needs to go up a separate chain of command. That is absolutely crucial because otherwise it's going to be viewed as competitive and that just isn't right. It's synergistic," Ling says.
  • The $6.3 billion 21st Century Cures Act authorized by Congress last year could help to launch HARPA, Wright says. Right now, $4.8 billion is slated to go to the NIH and $1 billion to states for opioid treatment and prevention.
  • Wright says, HARPA's success would depend on its ability to use NCI databases and other government assets.

Where it stands: "We've gone to the White House, we've gone to Congress, we've got bipartisan support," Wright says.

Ultimately, it would require congressional authorization — but they're asking the White House to launch it, potentially on a pilot basis. President Trump's budget proposed cutting money for the NIH, and there is a general trend toward consolidating across the federal government, raising questions about where funding for a new program would come from.

What we don't know: Where this will go. A spokesperson for the White House said there was no comment at this point.

Go deeper

10 mins ago - Politics & Policy

Republicans’ secret lobbying

Illustration: Shoshana Gordon/Axios

The five Senate Republicans who helped negotiate and draft the $1.2 trillion bipartisan infrastructure bill have been privately courting their Republican colleagues to pass the measure in the House.

Why it matters: House GOP leaders are actively urging their members to oppose the bill. The senators are working to undercut that effort as Monday shapes up as a do-or-die moment for the bipartisan bill.

CBC members nix border visit

A Haitian migrant carries a toddler on his shoulders today as he crosses the Rio Grande River. Photo: Pedro Pardo/AFP via Getty Images

Several members of the Congressional Black Caucus weighed visiting the U.S.-Mexico border this week to investigate the conditions faced by Haitian migrants and protest allegations of inhumane treatment by U.S. agents.

Why it matters: It's a thorny proposition both in terms of timing and messaging. Going assures a new wave of negative headlines for President Biden amid sinking popularity. And with congressional deadlines in the coming days over infrastructure, a possible government shutdown and debt-limit crisis, Democrats can't afford to lose any votes in the House.

Jan. 6 select committee subpoenas four Trump aides

Photo: Alex Wong/Getty Images

The Jan 6. select committee investigating the deadly Capitol riot has subpoenaed four aides to former President Trump for testimony and documents.

Why it matters: Former White House chief of staff Mark Meadows, former communications official Dan Scavino, former Defense Department official Kash Patel, and former Trump advisor Steve Bannon were all in touch "with the White House on or in the days leading up to the January 6th insurrection," the committee said in a release.